0001193125-26-219829
SEC filingQ1 FY2026 losses widened substantially to -$46.2M operating and -$42.1M net amid clinical advancement, reflecting higher development costs for later-stage product candidates and timing of R&D cash disbursements with no revenue.
Management emphasizes the inherent risks and uncertainties in pharmaceutical R&D and commercialization, rendering precise capital needs estimates challenging. BBOT expects R&D expenses to increase substantially with planned clinical and preclinical activities, including additional trials, exacerbating prior and future losses' adverse effects on working capital, product funding, profitability, and stock performance. The company could exhaust capital resources sooner than anticipated and continues evaluating broader business impacts. These factors frame Q1 results as a deliberate investment in pipeline progression amid sustained unprofitability, with liquidity and going concern considerations central to ongoing operations.